Novartis AG (NYSE:NVS) has entered an agreement with UK-based Artios Pharma to access DNA damage response targets having the potential of enhancing its radioligand drugs. The agreement will center around the development of cancer treatments through next-generation DDR targets discovery and validation. Novartis enters agreement with Artios According to the […]